Table 1.
Demographics and clinical characteristics of patient cohorts.
| NAC-treated cohort (N = 68)a | NAC-naïve cohort (N = 102)a | P valueb | |
|---|---|---|---|
| Age, years, median (IQR) | 67 (59–71) | 69 (62–75) | 0.010 |
| Sex | 0.53 | ||
| Female | 12 (18%) | 22 (22%) | |
| Male | 56 (82%) | 80 (78%) | |
| T-stage, TURBT | |||
| Ta | 0 (0%) | 1 (1%) | <0.001 |
| T1 | 2 (2.9%) | 22 (22%) | |
| T2 | 59 (87%) | 75 (74%) | |
| T3 | 1 (1.5%) | 0 (0%) | |
| T4 | 6 (8.8%) | 3 (3%) | |
| N-stage, TURBT | |||
| N0 | 58 (85%) | ||
| N1 | 7 (10%) | ||
| N2 | 3 (4.4%) | ||
| T-stage, RC | <0.001 | ||
| T0/CIS/Ta | 44 (67%) | 27 (26%) | |
| T1 | 3 (4.5%) | 8 (7.8%) | |
| T2 | 6 (9.1%) | 23 (23%) | |
| T3 | 9 (14%) | 35 (34%) | |
| T4 | 4 (6.1%) | 9 (8.8%) | |
| N-stage, RC | 0.059 | ||
| N0 | 59 (88%) | 79 (80%) | |
| N1 | 2 (3%) | 13 (13%) | |
| N2 | 3 (4.5%) | 6 (6.1%) | |
| N3 | 3 (4.5%) | 1 (1%) | |
| Pathologic downstaging after NAC | 44 (66%) | ||
| Complete response after NAC | 42 (63%) | ||
| Recurrence | 18 (28%) | 44 (44%) | 0.035 |
| 12-month recurrence | 10 (15%) | 29 (30%) | 0.034 |
| RFS, months, median (IQR) | 24 (23–25) | 24 (5–32) | 0.10 |
| 2-year survival | 57 (86%) | 73 (72%) | 0.037 |
| 5-year survival | 48 (73%) | 58 (57%) | 0.049 |
| OS, months, median (IQR) | 68 (54–82) | 72 (17–92) | 0.042 |
Abbreviations: CIS, carcinoma in situ; IQR, interquartile range.
aMedian (IQR); n (%).
bWilcoxon rank sum test; Person's χ2 test; Fisher exact test; Cox regression analysis.